EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early Real-World Experience of Switching to Faricimab for Macular Oedema Secondary to Vein Occlusion

Muiz Musadiq iD, Emer Chang iD, Abison Logeswaran iD, Matthew Azzopardi iD, Mohammed Musadiq, Yu Jeat Chong iD

Life · 16.07.2026 · 16 (7) · 1183

DOI: 10.3390/life16071183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 16.07.2026. Verfasst von Muiz Musadiq und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Royal Stoke University Hospital, Stoke-on-Trent ST4 6QG, UK. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the real-world effectiveness, durability, and safety of faricimab 6 mg in eyes with treatment-refractory retinal vein occlusion (RVO)-associated macular oedema (MO) in the United Kingdom (UK).

Methods

This was a retrospective, single-centre observational study of eyes with RVO that were switched to faricimab after prior treatment with previous anti-vascular endothelial growth factor (anti-VEGF) agents. Baseline demographics, treatment history, pinhole visual acuity (VA), optical coherence tomography (OCT) biomarkers, and injection intervals were recorded. Eyes were treated using a treat-and-extend regimen without a loading phase. Functional, anatomical, durability, and safety outcomes were assessed over follow-up.

Results

A total of 22 eyes from 22 patients were included, with a mean (SD) age of 67.9 (11.9) years and a mean (SD) RVO duration of 201.4 (153.1) weeks. Eyes had received a mean (SD) of 20.8 (16.9) prior anti-VEGF injections. The mean (SD) follow-up was 45.7 (15.8) weeks, with a mean (SD) of 5.9 (2.3) faricimab injections. There was no significant change in pinhole VA (53.5 (18.5) vs. 55.0 (18.8) letters, p = 0.08). The central subfield thickness (CST) reduced from 407.6 (102.1) to 377.0 (186.5) µm, and the maximum central retinal thickness from 483.6 (103.1) to 442.2 (187.2) µm, although these changes were not statistically significant (p > 0.05). The proportion of eyes with subretinal fluid (SRF) decreased from 18.2% to 4.5%, and intraretinal fluid (IRF) from 100% to 81.8%. Injection intervals between the first and second faricimab injections increased significantly from 4.9 (1.4) to 7.7 (3.4) weeks (final injection interval, p = 0.004). Six eyes (27.3%) discontinued faricimab, with three (13.6%) requiring an intravitreal dexamethasone implant following a suboptimal response. One eye (4.5%) developed transient intraocular pressure elevation; no cases of intraocular inflammation or endophthalmitis were observed.

Conclusions

In this heavily pre-treated, chronic RVO cohort, switching to faricimab without a loading phase resulted in stable visual acuity, modest but non-significant anatomical improvements, and a significant extension in treatment intervals. These findings suggest that faricimab may provide durability benefits and disease stabilisation in treatment-refractory RVO, although functional gains may be limited in chronic disease. Further prospective studies are required to define optimal switching strategies.

Schlagwörter

Stichwörter der Autor:innen

anti-VEGFfaricimabretinal vein occlusion

Autor:innen und Institutionen

  • Department of Ophthalmology, Royal Stoke University Hospital, Stoke-on-Trent ST4 6QG, UK.
  • Academic Unit of Ophthalmology, Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK.
  • Birmingham and Midland Eye Centre, Sandwell and West Birmingham NHS Trust, Birmingham B18 7QH, UK.
  • Moorfields Eye Hospital, London EC1V 2PD, UK.

ORCID-Profile: Muiz Musadiq, Emer Chang, Abison Logeswaran, Matthew Azzopardi, Yu Jeat Chong

Zitieren

APA

Musadiq, M., Chang, E., Logeswaran, A., Azzopardi, M., Musadiq, M., & Chong, Y. J. (2026). Early Real-World Experience of Switching to Faricimab for Macular Oedema Secondary to Vein Occlusion. Life, 16(7), 1183. https://doi.org/10.3390/life16071183

Vancouver

Musadiq M, Chang E, Logeswaran A, Azzopardi M, Musadiq M, Chong YJ. Early Real-World Experience of Switching to Faricimab for Macular Oedema Secondary to Vein Occlusion. Life. 2026;16(7):1183. doi:10.3390/life16071183

BibTeX
@article{Musadiq2026,
  author = {Musadiq, Muiz and Chang, Emer and Logeswaran, Abison and Azzopardi, Matthew and Musadiq, Mohammed and Chong, Yu Jeat},
  title = {Early Real-World Experience of Switching to Faricimab for Macular Oedema Secondary to Vein Occlusion},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {7},
  pages = {1183},
  doi = {10.3390/life16071183}
}
Kostenlos starten →